Tolerogenics

Tolerogenics is a South Korean clinical-stage biotechnology company focused on developing innovative cell therapies for autoimmune and inflammatory diseases. The company utilizes a proprietary platform to generate Tolerogenic Dendritic Cells (tDCs), which are designed to re-educate the immune system to recognize self-antigens and prevent pathological inflammation. Their lead candidate, TG-101, is currently in Phase 1 clinical trials for the treatment of Rheumatoid Arthritis, aiming to provide a disease-modifying alternative to traditional immunosuppressants. Beyond rheumatology, Tolerogenics is advancing a pipeline of tDC therapies for indications such as asthma, atopic dermatitis, and type 1 diabetes. The company's approach represents a shift toward precision immunology, seeking to restore long-term immune homeostasis through cellular regulation. By leveraging the natural role of dendritic cells in immune regulation, Tolerogenics aims to provide long-term remission for patients with chronic immune-mediated conditions.